Professor Adrian Krainer has been elected as a member of the National Academy of Sciences (NAS). He is one of 120 members and 26 international members chosen in 2020 in recognition of their distinguished and continuing achievements in original research.
Krainer is best known for his work on RNA splicing, as well as his work on Spinraza®, the first FDA-approved treatment for Spinal Muscular Atrophy (SMA). SMA is a neurodegenerative disease that is the leading genetic cause of infant death. The treatment Krainer developed is based on a biological process called RNA splicing, and it works to compensate for the genetic issue that causes the disease. It was this research that won Krainer the 2019 Breakthrough Prize in Life Science.